SCHEMBL12759331

SCHEMBL12759331

CCCCCC1CCC(c2ccc(COc3ccc(OCCCC)c(F)c3F)cc2)OC1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
CRHBP P24387 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
CRHR2 Q13324 1/20 0.35
ALOX5 P09917 2/20 0.34
PTGES O14684 1/20 0.32
PPARG P37231 1/20 0.32
PSEN1 P49768 1/20 0.32
FASN P49327 1/20 0.31
KDM4E B2RXH2 1/20 0.30
NPC1 O15118 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HPGD P15428 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12759320 0.97 MEN1 (0.33) MAPTSMN1; SMN2MEN1CRHBPHTT
SCHEMBL12759313 0.96 MAPT (0.33) MAPTSMN1; SMN2MEN1CRHBPHTT
SCHEMBL12759319 0.94 MAPT (0.33) MAPTSMN1; SMN2MEN1CRHBPHTT
SCHEMBL12759304 0.93 MEN1 (0.36) MAPTSMN1; SMN2MEN1CRHBPHTT
SCHEMBL12759310 0.93 MAPT (0.33) MAPTSMN1; SMN2MEN1CRHBPHTT
SCHEMBL12759325 0.92 MAPT (0.36) MAPTSMN1; SMN2MEN1CRHBPHTT
SCHEMBL12759301 0.90 MAPT (0.37) MAPTSMN1; SMN2MEN1CRHBPHTT
SCHEMBL12759318 0.89 FASN (0.35) MAPTSMN1; SMN2MEN1CRHBPHTT
SCHEMBL12759333 0.89 ALOX5 (0.35) MAPTSMN1; SMN2MEN1CRHBPHTT
SCHEMBL12759307 0.88 FASN (0.37) MAPTSMN1; SMN2MEN1CRHBPHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7914862-B2 Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device CHISSO CORPORATION (JP) 2011-03-29 US disclosed
US-7914862-B2 Liquid crystal compound having negative dielectric anisotropy, liquid crystal composition, and liquid crystal display device CHISSO CORPORATION (JP) 2011-03-29 US disclosed
EP-2272837-A1 LIQUID CRYSTALLINE COMPOUND WITH NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE Chisso Corporation (JP) 2011-01-12 EP disclosed
US-20090278088-A1 LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2009-11-12 US disclosed
US-20090278088-A1 LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO CORPORATION (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090278088-A1 LIQUID CRYSTAL COMPOUND HAVING NEGATIVE DIELECTRIC ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE OCIAD2, OCIAD1, CCDC22 MAPT 375/4885SMN1; SMN2 4615/4885MEN1 3564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.